Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

NCT04181762 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

275

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated by sponsor due to futility analysis

Conditions

Lupus Nephritis

Interventions

DRUG: secukinumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals